ANGPTL4 & Adipose RNA Update

A modest week: a mechanistic paper shows DHA raises adipocyte Angptl4 via PPARγ to suppress LPL, a sarcopenia atlas casts adipose-derived ANGPTL4 as a paracrine brake on muscle regeneration, and a J Control Release review places adipose RNAi in Phase 1/2a among extrahepatic delivery platforms.

A new PNAS paper introduces an adipose-directed antisense oligonucleotide that preserves lean mass and boosts fat-selective weight loss alongside semaglutide, while a large Mendelian-randomization study adds human genetic support for ANGPTL4 inhibition as a kidney-protective strategy.

A thin week for ANGPTL4-specific news, but one strong hit on the delivery side — a microneedle/LNP-mRNA platform that directly targets subcutaneous adipose tissue to reverse fibrotic changes in skin disease.

A genuinely thin week — the 8-day PubMed window surfaced 14 candidates, but the four that were actually on-topic (two direct ANGPTL4-in-cancer mechanism papers, an adipokine/sleep review touching ANGPTL4, and an adipose-targeted circRNA-LNP weight-loss study) had all already been covered in prior cycles, and the remaining hits were off-topic (bovine genetics, wound-healing exosomes, autism modeling, Duchenne muscular dystrophy). No new on-topic papers this week.

A thin week for new science — one paper adds ANGPTL4 to the growing list of endometriosis biomarkers, and one describes an adipose-targeted lipid nanoparticle (not RNA-loaded, but relevant delivery-platform work) for reprogramming obese adipose tissue immunity.

It's a thin week on the core beat — every directly on-topic ANGPTL4 or adipose-RNA-delivery paper indexed in the past 8 days had already been covered in a prior episode, so this issue instead surfaces two adjacent adipose tissue macrophage papers relevant to metabolic complications and RNAi-based therapeutic strategies.

A thin week for new ANGPTL4-specific literature, but one strong hit on the RNA-delivery-to-metabolic-tissue side: a circular RNA/LNP formulation delivering GDF15 shows sustained weight loss and adipose thermogenic activation in obese mice.

A quiet week — the PubMed search returned 12 hits in the last 8 days, but 10 of the 12 had already been covered in prior episodes and the remaining 2 are off-topic, so there is no new ANGPTL4 or adipose-RNA-delivery research to report this cycle.

The week's strongest signal is a Molecular Therapy paper using antibody-targeted lipid-coated nanoparticles to deliver siRNA into a specific pathogenic adipose stromal cell population — a concrete adipose-RNA-delivery advance — alongside a cluster of new mechanistic data tying ANGPTL4 to cancer metastasis, immune evasion, and renal fibrosis, plus a registered systematic-review protocol on ANGPTL3/ANGPTL4/APOC3 inhibitors for hypertriglyceridemia-driven pancreatitis.

A thin week for ANGPTL4-specific literature — every ANGPTL4 hit in the 8-day PubMed window duplicated prior coverage — but three adjacent papers are worth a look: two on adipocyte differentiation mechanisms and one on an siRNA nanovesicle delivery platform.